Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 128Carboplatin 126Pemetrexed 106Cisplatin 79Paclitaxel 60osimertinib 54Nivolumab 53Docetaxel 52durvalumab 48Specimen Handling 40Magnetic Resonance Spectroscopy 36Gemcitabine 36Radiosurgery 29atezolizumab 27130-nm albumin-bound paclitaxel 27Cetuximab 26Radiotherapy 23Ipilimumab 22Drug Therapy 22cemiplimab 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Radiation 12Biopsy 12lazertinib 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × tisotumab vedotin × 90 days × Clear all
NCT03485209 2026-04-20

innovaTV 207

Seagen Inc.

Phase 2 Active not recruiting
350 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡